Selected articles
Articles for label Roubec Jaromír are displayed.. Show all articles
STRN‑ALK fusion, rare variant of ALK gene – case report
05/2021 MUDr. Jaromír Roubec, Ph.D.; MUDr. Jaroslav Krátký
In connection with their own case report, the authors discuss the issue of rare mutations in the gene for anaplastic lymphoma kinase (ALK), known mechanisms of increased tumorigenesis of such mutated non-small cell lung cancer tumors and the possibilities of their therapeutic management using tyrosine kinase inhibitors. Literature sources and documented cases of a rare STRN-ALK fusion mutation are presented.
ENTIRE ARTICLE
In connection with their own case report, the authors discuss the issue of rare mutations in the gene for anaplastic lymphoma kinase (ALK), known mechanisms of increased tumorigenesis of such mutated non-small cell lung cancer tumors and the possibilities of their therapeutic management using tyrosine kinase inhibitors. Literature sources and documented cases of a rare STRN-ALK fusion mutation are presented.
The role of concomitant chemoradiotherapy in the treatment of non‑small cell lung cancer
01/2021 MUDr. Jaromír Roubec, Ph.D.; MUDr. Jaromír Richter
In the overview the authors discuss the actual approaches in the concomitant chemoradiotherapy based on the previous results and meta-analysis and discuss the new possibilities in the combined chemoradiotherapy and immunotherapy of the locoregional advanced non-small cell lung cancer.
ENTIRE ARTICLE
In the overview the authors discuss the actual approaches in the concomitant chemoradiotherapy based on the previous results and meta-analysis and discuss the new possibilities in the combined chemoradiotherapy and immunotherapy of the locoregional advanced non-small cell lung cancer.
Atezolizumab in the treatment of small cell lung cancer
01/2020 MUDr. Jaromír Roubec, Ph.D.
In this overview are presented data and results of the combination check-point inhibitor atezolizumab and chemotherapy from the clinical trial IMpower133 in the extensive-stage small cell lung cancer. This data new support introducing of this therapeutic modality into clinical praxis based on the prolonged progression free survival and overall survival. Discussed is the problem of the therapy of the small cell lung cancer and next possibilities with using of the immunotherapy in the combination in this time used therapies and next perspectives in this area.
ENTIRE ARTICLE
In this overview are presented data and results of the combination check-point inhibitor atezolizumab and chemotherapy from the clinical trial IMpower133 in the extensive-stage small cell lung cancer. This data new support introducing of this therapeutic modality into clinical praxis based on the prolonged progression free survival and overall survival. Discussed is the problem of the therapy of the small cell lung cancer and next possibilities with using of the immunotherapy in the combination in this time used therapies and next perspectives in this area.
Chemotherapy of lung cancer
05/2019 MUDr. Jaromír Roubec, Ph.D.
In a short review, the author presents the historical development of the use of chemotherapy in the treatment of non-small cell and small cell lung cancer from the early 1990s to the present.
ENTIRE ARTICLE
In a short review, the author presents the historical development of the use of chemotherapy in the treatment of non-small cell and small cell lung cancer from the early 1990s to the present.
Individualized treatment of patients with non‑small cell lung cancer
04/2018 MUDr. Jaromír Roubec, Ph.D.
Author in this article describes crucial periods and changes in the attitude to the therapy of the local progressive and metastatic bronchogenic carcinoma during the last three decades with the accent on the rapid progress in the personalized target therapy and immunotherapy of this disease together with next perspectives in the research and clinical practice.
ENTIRE ARTICLE
Author in this article describes crucial periods and changes in the attitude to the therapy of the local progressive and metastatic bronchogenic carcinoma during the last three decades with the accent on the rapid progress in the personalized target therapy and immunotherapy of this disease together with next perspectives in the research and clinical practice.
Afatinib in clinical practice – patient case study with eighteen months of progression‑free survival and high quality of life
01/2018 MUDr. Jaromír Roubec, Ph.D., MUDr. Radoslava Černeková
The author presents the case report of the patient treated with afatinib. This is a man, the year 1961, in which, on June 3, 2014, a perthoraxal puncture of the left lung bearing under CT control was diagnosed with primary pulmonary adenocarcinoma of the acinaric micropapillary type according to TNM classification T4N3M1b grade IV, with bilateral metastatic lung disease, carcinomatous lymphangiitis, exudate, and metastases to the liver and thyroid. The metastasis of the thyroid gland has been verified punctually and compared to a sample of tissue taken from the lung. Performance status of ECOG 1. Molecular genetic examination on 20 June 2014 detected EGFR activation mutation in L858R exon 21, EGFR gene amplification was detected, ALK and ROS1 gene reconstruction was not found. The patient was only an occasional smoker, the patient visited his physician for weight loss of seven kilograms in three months, and dyspnoea with dry cough. Early treatment with afatinib was initiated on June 27, 2014, less than one month after tissue collection. The patient was on regular monitoring with long-term severe partial regression of lung, liver and thyroid involvement in ECOG 0 performance improvement until disease progression after 18 months of CNS treatment with a total survival of 28 months.
ENTIRE ARTICLE
The author presents the case report of the patient treated with afatinib. This is a man, the year 1961, in which, on June 3, 2014, a perthoraxal puncture of the left lung bearing under CT control was diagnosed with primary pulmonary adenocarcinoma of the acinaric micropapillary type according to TNM classification T4N3M1b grade IV, with bilateral metastatic lung disease, carcinomatous lymphangiitis, exudate, and metastases to the liver and thyroid. The metastasis of the thyroid gland has been verified punctually and compared to a sample of tissue taken from the lung. Performance status of ECOG 1. Molecular genetic examination on 20 June 2014 detected EGFR activation mutation in L858R exon 21, EGFR gene amplification was detected, ALK and ROS1 gene reconstruction was not found. The patient was only an occasional smoker, the patient visited his physician for weight loss of seven kilograms in three months, and dyspnoea with dry cough. Early treatment with afatinib was initiated on June 27, 2014, less than one month after tissue collection. The patient was on regular monitoring with long-term severe partial regression of lung, liver and thyroid involvement in ECOG 0 performance improvement until disease progression after 18 months of CNS treatment with a total survival of 28 months.